Last updated: 24 June 2022 at 8:54am EST

James Lim Net Worth

The estimated Net Worth of James C Lim is at least $14.5 million dollars as of 3 September 2021. James Lim owns over 14,584 units of Becton Dickinson & Co stock worth over $8,027,719 and over the last 12 years he sold BDX stock worth over $6,513,471. In addition, he makes $0 as Executive Vice President, President et Greater Asia at Becton Dickinson & Co.

James Lim BDX stock SEC Form 4 insiders trading

James has made over 17 trades of the Becton Dickinson & Co stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 14,584 units of BDX stock worth $1,964,902 on 3 September 2021.

The largest trade he's ever made was exercising 33,966 units of Becton Dickinson & Co stock on 9 August 2019 worth over $2,554,583. On average, James trades about 3,898 units every 74 days since 2012. As of 3 September 2021 he still owns at least 34,352 units of Becton Dickinson & Co stock.

You can see the complete history of James Lim stock trades at the bottom of the page.

James Lim biography

James Lim is the Executive Vice President, President, Greater Asia at Becton Dickinson & Co.

How old is James Lim?

James Lim is 55, he's been the Executive Vice President, President et Greater Asia of Becton Dickinson & Co since 2012. There are 20 older and 13 younger executives at Becton Dickinson & Co. The oldest executive at Becton Dickinson & Co. is Marshall Larsen, 71, who is the Lead Independent Director.

What's James Lim's mailing address?

James's mailing address filed with the SEC is C/O BECTON, DICKINSON AND COMPANY, , FRANKLIN LAKES, NJ, 07417.

Insiders trading at Becton Dickinson & Co

Over the last 22 years, insiders at Becton Dickinson & Co have traded over $106,782,599 worth of Becton Dickinson & Co stock and bought 23,860 units worth $1,771,828 . The most active insiders traders include Edward J Ludwig, William M Brown et Vincent A Forlenza. On average, Becton Dickinson & Co executives and independent directors trade stock every 20 days with the average trade being worth of $4,349,205. The most recent stock trade was executed by Roland Goette on 14 August 2024, trading 5,295 units of BDX stock currently worth $701,799.

What does Becton Dickinson & Co do?

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.

Complete history of James Lim stock trades at Becton Dickinson & Co

Initié	Trans. Transaction	Prix total
James C Lim Vice-président exécutif	Exercice d'option	$1,964,902 3 Sep 2021
James C Lim Vice-président exécutif	Vente	$828,721 28 May 2021
James C Lim Vice-président exécutif	Exercice d'option	$1,725,689 6 Sep 2019
James C Lim Vice-président exécutif	Exercice d'option	$2,554,583 9 Aug 2019
James C Lim Vice-président exécutif	Exercice d'option	$212,523 8 Aug 2019
James C Lim Vice-président exécutif	Vente	$1,257,606 8 Nov 2018
James C Lim Vice-président exécutif	Vente	$714,210 8 Sep 2017
James C Lim Vice-président exécutif	Vente	$870,559 9 May 2016
James C Lim Vice-président exécutif	Exercice d'option	$602,256 18 May 2015
James C Lim Vice-président exécutif	Exercice d'option	$407,679 15 Mar 2013

Becton Dickinson & Co executives and stock owners

Becton Dickinson & Co executives and other stock owners filed with the SEC include:

Vincent Forlenza,
Executive Chairman of the Board
Patrick Kaltenbach,
Executive Vice President, President - Life Sciences
Thomas Polen,
President, Chief Executive Officer, Chief Operating Officer, Director
Christopher Reidy,
Chief Financial Officer, Executive Vice President, Chief Administrative Officer
Alberto Mas,
Executive Vice President, President - Medical Segment
Thomas E. Polen Jr.,
Pres, CEO & Chairman
Samrat Khichi,
Executive Vice President - Public Policy and Regulatory Affairs
Alexandre Conroy,
Executive Vice President, Chief Integrated Supply Chain Officer
Vincent A. Forlenza,
Exec. Chairman
Samrat S. Khichi,
Exec. VP of Regulatory & Gov. Affairs and Gen. Counsel
Alberto Mas,
Exec. VP & Pres of the Medical Segment
Samrat S. Khichi Esq.,
Exec. VP of Corp. Devel., Public Policy & Regulatory Affairs and Gen. Counsel
Christopher R. Reidy,
Exec. VP, CFO & Chief Admin. Officer
Simon D. Campion,
Exec. VP & Pres of Interventional Segment
Christopher DelOrefice,
Exec. VP & CFO
Marshall Larsen,
Lead Independent Director
Bertram Scott,
Independent Director
Claire Fraser,
Independent Director
Christopher Jones,
Independent Director
Catherine Burzik,
Independent Director
Claire Pomeroy,
Independent Director
Timothy Ring,
Independent Director
Rebecca Rimel,
Independent Director
David Melcher,
Independent Director
Jeffrey Henderson,
Independent Director
R. Andrew Eckert,
Independent Director
John DeFord,
Executive Vice President, Chief Technology Officer
James Lim,
Executive Vice President, President, Greater Asia
Thomas Spoerel,
Chief Accounting Officer, Principal Accounting Officer, Vice President, Controller
Monique Dolecki,
Investor Relations Contact Officer
Charles Bodner,
Senior Vice President, Corporate Finance
Roland Goette,
Executive Vice President, President - EMEA
Simon Campion,
Executive Vice President and President, BD Interventional Segment
Betty Larson,
Executive Vice President- Human Resources, Chief Human Resources
Denise Fleming,
Exec. VP of Technology & Global Services and Chief Information Officer
Francesca M. DeMartino,
Sr. VP of Investor Relations
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.,
Sr. VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board
Troy Kirkpatrick,
VP of PR
Elizabeth McCombs,
Exec. VP & Chief Technology Officer
Michelle Quinn,
Sr. VP and Chief Ethics & Compliance Officer
Jerry Flasz,
Exec. VP of Global Services & Chief Information Officer
Dr. John A. DeFord,
Exec. VP of R&D and CTO
Thomas J. Spoerel,
Sr. VP, Controller & Chief Accounting Officer
Joanne Waldstreicher,
Director
Gary A Mecklenburg,
Director
John E Gallagher,
VP, Corp Finance and Treasurer
Linda M Tharby,
Segment Pres. Life Sciences
Wilard J Jr Overlock,
Director
Nabil Shabshab,
Senior Vice President
Jeffrey S Sherman,
VP and General Counsel
Basil Anderson,
Director
Ellen R Strahlman,
Senior Vice President
James F Orr,
Director
William A Tozzi,
VP and Controller
Gary M Cohen,
President - BD Medical Systems
Stephen Sichak,
Senior Vice President
Henry P Jr Becton,
Director
Carrie L Byington,
Director
Edward Degraan,
Director
William A Kozy,
Pres - BD CLS and Cmpy Oper
Alfred Sommer,
Director
David Shan,
EVP and Chief ISC Officer
Shana Carol Neal,
EVP and Chief People Officer
John P Groetelaars,
EVP
James W Borzi,
EVP & Chief Supply Chain Offcr
Suketu Upadhyay,
Senior VP and Controller
Adel Mahmoud,
Director
Jerome V Hurwitz,
Senior Vice President
Donna M Boles,
Sr. Exec VP - Human Resources
David V Elkins,
Executive VP and CFO
David T Durack,
Senior Vice President
William E. Rhodes,
Senior Vice President
Joseph Mercurio,
VP and Corporate Controller
Patricia B Shrader,
Senior Vice President
Scott P Bruder,
SrVP; Chief Technology Officer
Cathy E. Minehan,
Director
Margeretha Af Ugglas,
Director
Edward J Ludwig,
Chairman, President and CEO
James E Perrella,
Director
Alfred John Hanson,
Executive Vice President
John R Considine,
Executive VP and CFO
Jean Marc Dageville,
VP - Human Resources
Harry N Beaty,
Director
Frank Albert Olson,
Director
Bridget M Healy,
VP, Gen Counsel and Secy
Christopher Del Orefice,
EVP & Chief Financial Officer
Antoine C Ezell,
EVP, President NA & CMO
David Hickey,
EVP & President, Life Sciences
William M Brown,
Director
Rishi Grover,
EVP and Chief ISC Officer
Michael David Garrison,
EVP & President Medical
Richard Byrd,
EVP & President Interventional
Pavan Kumar Mocherla,
EVP & President Greater Asia
Michael Feld,
EVP & President, Life Sciences